# Risk Factor Control Before Orthopedic Surgery

Study · id `cardio:ct-nct01837069` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01837069](<https://clinicaltrials.gov/study/NCT01837069>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01837069

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 198 participants.

## Technical summary

Registry record NCT01837069. Randomized; no masking; primary purpose prevention. Start 2014-02 (registry gives no type); primary completion 2018-04-02 (actual). Results posted on 2020-07-27.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 198 participants (enrolled count; ClinicalTrials.gov record NCT01837069, source copy `cardio:ctgov-nct01837069-2020-07-27`, retrieved 2026-10-26)
- Start date: 2014-02 (registry gives no type) (ClinicalTrials.gov record NCT01837069, source copy `cardio:ctgov-nct01837069-2020-07-27`, retrieved 2026-10-26)
- Primary completion: 2018-04-02 (actual) (ClinicalTrials.gov record NCT01837069, source copy `cardio:ctgov-nct01837069-2020-07-27`, retrieved 2026-10-26)
- Completion: 2018-04-02 (actual) (ClinicalTrials.gov record NCT01837069, source copy `cardio:ctgov-nct01837069-2020-07-27`, retrieved 2026-10-26)
- Results first posted: 2020-07-27 (ClinicalTrials.gov record NCT01837069, source copy `cardio:ctgov-nct01837069-2020-07-27`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01837069, source copy `cardio:ctgov-nct01837069-2020-07-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01837069-2020-07-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Risk Factor Control Before Orthopedic Surgery
- Acronym: OPTMIZE-OS
- Condition: Osteoarthritis
- Condition: Cardiovascular Disease
- Intervention (Drug): Metoprolol
- Intervention (Drug): Lisinopril
- Intervention (Drug): Atorvastatin
- Intervention (Behavioral): Lifestyle counseling
- Lead sponsor: NYU Langone Health
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Metoprolol (`cardio:metoprolol`)
- Registry intervention name matches this record: Lisinopril (`cardio:lisinopril`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as the lead sponsor: NYU Langone Health (`cardio:org-nyu-langone-health`)

## Provenance

Content hash: b094ca78752badcbea9b4ae88cca40e501275d0df457287f6f6d8de22ed3c7bf
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
